FDA Approval Expected Monday of Ketamine-derived “Spravato”
TAKE HOME POINTS: SpravatoTM, a form of ketamine, will be FDA approved on Monday for Treatment Resistant Depression and for Major Depression with suicidality. FDA approval will result in insurance coverage for this form of ketamine, for this purpose, which will make it affordable for millions of suffering patients. Although it is...